BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He W, Li C, Chen Q, Xiang T, Wang P, Pang J. Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention. Aging Clin Exp Res 2020;32:2065-72. [DOI: 10.1007/s40520-019-01393-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Golledge J, Thanigaimani S. Role of Sclerostin in Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2022;42:e187-202. [PMID: 35546488 DOI: 10.1161/ATVBAHA.122.317635] [Reference Citation Analysis]
2 Yu S, Li D, Zhang N, Ni S, Sun M, Wang L, Xiao H, Liu D, Liu J, Yu Y, Zhang Z, Yeung STY, Zhang S, Lu A, Zhang Z, Zhang B, Zhang G. Drug discovery of sclerostin inhibitors. Acta Pharm Sin B 2022;12:2150-70. [PMID: 35646527 DOI: 10.1016/j.apsb.2022.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mayer O, Bruthans J, Seidlerová J, Gelžinský J, Kučera R, Karnosová P, Mateřánková M, Rychecká M, Wohlfahrt P, Cífková R, Filipovský J, Vermeer C. Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. Biomark Med 2021;15:1465-77. [PMID: 34668399 DOI: 10.2217/bmm-2021-0168] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Kern A, Stompór T, Kiewisz J, Kraziński BE, Kiezun J, Kiezun M, Górny J, Sienkiewicz E, Gromadziński L, Onichimowski D, Bil J. The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up. J Pers Med 2021;11:186. [PMID: 33800939 DOI: 10.3390/jpm11030186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]